Literature DB >> 31780468

Aspirin for primary prevention of CVD in CKD: where do we stand?

Hugh Gallagher1, Mark Lown2, Ahmet Fuat3, Paul Roderick2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31780468      PMCID： PMC6867208          DOI： 10.3399/bjgp19X706661

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN： 0960-1643            Impact factor:   5.386


× No keyword cloud information.
  10 in total

1.  Prescription Rates of Cardiovascular Medications in a Large UK Primary Care Chronic Kidney Disease Cohort.

Authors:  Rupert Major; David Shepherd; Graham Warwick; Nigel Brunskill
Journal:  Nephron       Date:  2016-04-30       Impact factor: 2.847

2.  Does an Aspirin a Day Keep the Doctor Away?

Authors:  Taimur Dad; Daniel E Weiner
Journal:  Am J Kidney Dis       Date:  2016-11-23       Impact factor: 8.860

3.  Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.

Authors:  Kunihiro Matsushita; Marije van der Velde; Brad C Astor; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh; Ron T Gansevoort
Journal:  Lancet       Date:  2010-05-17       Impact factor: 79.321

4.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.

Authors: 
Journal:  BMJ       Date:  2002-01-12

5.  Acute myocardial infarction in patients with chronic kidney disease: how are the most vulnerable patients doing?

Authors:  Gautam R Shroff; Charles A Herzog
Journal:  Kidney Int       Date:  2013-08       Impact factor: 10.612

6.  Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial.

Authors:  Meg J Jardine; Toshiharu Ninomiya; Vlado Perkovic; Alan Cass; Fiona Turnbull; Martin P Gallagher; Sophia Zoungas; Hiddo J Lambers Heerspink; John Chalmers; Alberto Zanchetti
Journal:  J Am Coll Cardiol       Date:  2010-09-14       Impact factor: 24.094

7.  Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.

Authors:  Louise Bowman; Marion Mafham; Karl Wallendszus; Will Stevens; Georgina Buck; Jill Barton; Kevin Murphy; Theingi Aung; Richard Haynes; Jolyon Cox; Aleksandra Murawska; Allen Young; Michael Lay; Fang Chen; Emily Sammons; Emma Waters; Amanda Adler; Jonathan Bodansky; Andrew Farmer; Roger McPherson; Andrew Neil; David Simpson; Richard Peto; Colin Baigent; Rory Collins; Sarah Parish; Jane Armitage
Journal:  N Engl J Med       Date:  2018-08-26       Impact factor: 91.245

8.  Aspirin and cardiovascular primary prevention in non-endstage chronic kidney disease: A meta-analysis.

Authors:  Rupert W Major; Issaam Oozeerally; Simon Dawson; Helen Riddleston; Laura J Gray; Nigel J Brunskill
Journal:  Atherosclerosis       Date:  2016-06-10       Impact factor: 5.162

9.  Estimating the financial cost of chronic kidney disease to the NHS in England.

Authors:  Marion Kerr; Benjamin Bray; James Medcalf; Donal J O'Donoghue; Beverley Matthews
Journal:  Nephrol Dial Transplant       Date:  2012-08-05       Impact factor: 5.992

10.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.

Authors:  Colin Baigent; Lisa Blackwell; Rory Collins; Jonathan Emberson; Jon Godwin; Richard Peto; Julie Buring; Charles Hennekens; Patricia Kearney; Tom Meade; Carlo Patrono; Maria Carla Roncaglioni; Alberto Zanchetti
Journal:  Lancet       Date:  2009-05-30       Impact factor: 79.321
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.